Furthermore, combining paclitaxel with the JAK2-selective inhibitor CYT387 in patient-derived ovarian cancer cells suppressed the paclitaxel-induced activation of the JAK2/STAT3 pathway, as well as the expression of CSC and embryonic stem cell markers in the surviving cells. Here, JAK2 is linked to ovarian cancer.